alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5110 Antiparietal antibody immunological test system. ( a ) *Identification.* An antiparietal antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the specific antibody for gastric parietal cells in serum and other body fluids. Gastric parietal cells are those cells located in the stomach that produce a protein that enables vitamin B12 to be absorbed by the body. The measurements aid in the diagnosis of vitamin B12 deficiency (or pernicious anemia), atrophic gastritis (inflammation of the stomach), and autoimmune connective tissue diseases (diseases resulting when the body produces antibodies against its own tissues).
( b ) *Classification.* Class II (performance standards).
STEAM ELECTRIC CBI REPLACEMENT PAGE

EPA-HQ-OW-2009-0819

DCN: SE03584

THE FOLLOWING HAS BEEN REMOVED BECAUSE IT CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI) PER 40 CFR PART 2, SUBPART B.
IN THE SUPREME COURT OF PENNSYLVANIA

WESTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

CHARMAINE PFENDER,

Petitioner

:

:

:

:

:

:

:

:

:

:

:

No. 218 WAL 2017

Petition for Allowance of Appeal from 

the Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 24th day of October, 2017, the Petition for Allowance of Appeal

is DENIED.
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5620 Breathing mouthpiece. ( a ) *Identification.* A breathing mouthpiece is a rigid device that is inserted into a patient's mouth and that connects with diagnostic or therapeutic respiratory devices.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 868.9.
[47 FR 31142, July 16, 1982, as amended at 65 FR 2313, Jan. 14, 2000]
# C_2015389EN.01004401.xml

| 23.11.2015 | EN | Official Journal of the European Union | C 389/44 |
| --- | --- | --- | --- |

23.11.2015

EN

Official Journal of the European Union

C 389/44

---

Judgment of the General Court of 23 September 2015 — Cristiano di Thiene v OHIM — Nautica Apparel (AERONAUTICA)

(Case T-193/14) (1)

1

((Community trade mark - Opposition proceedings - Application for Community word mark AERONAUTICA - Earlier Community word marks NAUTICA and NAUTICA BLUE - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009))

(2015/C 389/47)

Language of the case: English

Parties

Parties

Applicant: Cristiano di Thiene SpA (Thiene, Italy) (represented by: F. Fischetti and F. Celluprica, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: P. Bullock and N. Bambara, acting as Agents)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM, intervener before the General Court: Nautica Apparel, Inc. (New York, New York, United States) (represented by: C. Hawkes, Solicitor, and B. Brandreth, Barrister)

Other party to the proceedings before the Board of Appeal of OHIM, intervener before the General Court:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 10 January 2014 (Case R 96/2013-4) concerning opposition proceedings between Nautica Apparel, Inc. and Cristiano di Thiene SpA.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Cristiano di Thiene SpA to pay the costs. |
| --- | --- |

2.

Orders Cristiano di Thiene SpA to pay the costs.

---

(1)  OJ C 151, 19.5.2014.

1

---
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.6890 Intraoral dental wax. ( a ) *Identification.* Intraoral dental wax is a device made of wax intended to construct patterns from which custom made metal dental prostheses, such as crowns and bridges, are cast. In orthodontic dentistry, the device is intended to make a pattern of a patient's bite to make study models of the teeth.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9. If the device is not labeled or otherwise represented as sterile, it is exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[52 FR 30097, Aug. 12, 1987, as amended at 59 FR 63009, Dec. 7, 1994; 66 FR 38800, July 25, 2001]
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.4250 Cardiopulmonary bypass temperature controller. ( a ) *Identification.* A cardiopulmonary bypass temperature controller is a device used to control the temperature of the fluid entering and leaving a heat exchanger.
( b ) *Classification.* Class II (performance standards).
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         Center for Scientific Review Special Emphasis Panel, Topics in Epidemiology.                    

*Date:*                         March 31-April 1, 2010.                    

*Time:*                         8:30 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).                    

*Contact Person:*                         Suzanne Ryan, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3139, Bethesda, MD 20892, (301) 435-1712,                         *ryansj@csr.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 1, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-4749 Filed 3-4-10; 8:45 am]

BILLING CODE 4140-01-P
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3560 Lithium test system. ( a ) *Identification.* A lithium test system is a device intended to measure lithium (from the drug lithium carbonate) in serum or plasma. Measurements of lithium are used to assure that the proper drug dosage is administered in the treatment of patients with mental disturbances, such as manic-depressive illness (bipolar disorder).
( b ) *Classification.* Class II.
Exhibit 31.2

CERTIFICATION

I, Kenneth Torosian, certify that:

1. I have reviewed  this  quarterly  report on Form 10-Q of Medialink  Worldwide
Incorporated;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact  necessary to make the statements
made, in light of the  circumstances  under which such statements were made, not
misleading with respect to the period covered by this report;

3.  Based  on my  knowledge,  the  financial  statements,  and  other  financial
information included in this report, fairly present in all material respects the
financial  condition,  results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4.  The  registrant's  other  certifying  officer  and  I  are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

      a)    Designed such  disclosure  controls and  procedures,  or caused such
            disclosure   controls  and  procedures  to  be  designed  under  our
            supervision,  to ensure that  material  information  relating to the
            registrant,  including its consolidated subsidiaries,  is made known
            to us by others  within  those  entities,  particularly  during  the
            period in which this report is being prepared;

      b)    Evaluated the effectiveness of the registrant's  disclosure controls
            and  procedures and presented in this report our  conclusions  about
            the effectiveness of the disclosure  controls and procedures,  as of
            the  end  of the  period  covered  by  this  report  based  on  such
            evaluation; and

      c)    Disclosed  in this  report any change in the  registrant's  internal
            control  over   financial   reporting   that  occurred   during  the
            registrant's   most  recent  fiscal   quarter  that  has  materially
            affected,   or  is  reasonably  likely  to  materially  affect,  the
            registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed,  based on our
most recent  evaluation of internal  control over  financial  reporting,  to the
registrant's  auditors  and the audit  committee  of the  registrant's  board of
directors (or persons performing the equivalent functions):

      a)    All significant  deficiencies and material  weaknesses in the design
            or operation of internal control over financial  reporting which are
            reasonably  likely to adversely affect the  registrant's  ability to
            record, process, summarize and report financial information; and

      b)    Any fraud,  whether or not  material,  that  involves  management or
            other  employees  who have a  significant  role in the  registrant's
            internal control over financial reporting.


Dated: November 14, 2005

/s/ Kenneth Torosian
--------------------
Name: Kenneth Torosian
Title: Chief Financial Officer
**Exhibit 99.1**

 

**Formof Certification**

 

**CERTIFICATIONPURSUANT TO SECTION 906**

 

**OFTHE SARBANES-OXLEY ACT OF 2002**

 

In connectionwith the Quarterly Report on Form 10-Q of ebix.com, Inc. (the “Company”) forthe quarterly period ended March 31, 2003 as filed with the Securities andExchange Commission on the date hereof (the “Report”), I, Robin Raina, ChiefExecutive Officer of the Company, certify, pursuant to section 906 of theSarbanes-Oxley Act of 2002, that:

 

(1)                                  the Report fullycomplies with the requirements of section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and

 

(2)                                  the informationcontained in the Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.

 
| By:                     | /s/ Robin Raina |   |   |
|-------------------------|-----------------|--------|--------|
|                    |            |
| Name:                   | Robin Raina     |   |   |
|                    |            |
| Chief Executive Officer |            |
|                    |            |
| May 14, 2003            |            |
|                         |                 |        |        |  |

 

A signed original of this written statement required by Section 906 hasbeen provided to ebix.com, Inc. and will be retained by ebix.com, Inc. andfurnished to the Securities and Exchange Commission or its staff upon request.

 

----
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                          22,447
<SECURITIES>                                         0
<RECEIVABLES>                                    9,821
<ALLOWANCES>                                         0
<INVENTORY>                                        764
<CURRENT-ASSETS>                                46,875
<PP&E>                                         204,462
<DEPRECIATION>                                   1,433
<TOTAL-ASSETS>                                 261,082
<CURRENT-LIABILITIES>                            9,714
<BONDS>                                        110,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       225,805
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   261,082
<SALES>                                          2,261
<TOTAL-REVENUES>                                 5,313
<CGS>                                            2,491
<TOTAL-COSTS>                                   12,669
<OTHER-EXPENSES>                                  (36)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (7,320)
<INCOME-TAX>                                        62
<INCOME-CONTINUING>                            (7,382)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (6,789)
<EPS-BASIC>                                     (0.18)
<EPS-DILUTED>                                   (0.18)


</TABLE>
§ 830.320 Submission of unique device identification information. ( a ) *Designation of contact for device identification.* Each labeler must designate an individual to serve as the point of contact with FDA on matters relating to the identification of medical devices marketed by the labeler. The contact for device information is responsible for ensuring FDA is provided with all information required by this part. The contact for device information may authorize an issuing agency or any other person to provide information to FDA on behalf of the labeler.
( b ) *Information shall be submitted via electronic means.* All information required by this subpart shall be submitted electronically to FDA's Global Unique Device Identification Database (GUDID) in a format that we can process, review, and archive, unless the labeler has obtained a waiver from electronic submission of unique device identifier (UDI) data.
( c ) *Waiver from electronic submission.* ( 1 ) A labeler may request a waiver from electronic submission of UDI data by submitting a letter addressed to the appropriate Center Director explaining why electronic submission is not technologically feasible; send the request by email to: *udi@fda.hhs.gov ,* or by correspondence to: UDI Regulatory Policy Support, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3293, Silver Spring, MD 20993-0002.
( 2 ) If the establishment where the labeler is located has obtained a waiver from electronic submission of registration and listing information under section 510(p) of the Federal Food, Drug, and Cosmetic Act, the labeler is deemed to have a waiver from electronic submission of UDI data.
( 3 ) A labeler that has a waiver from electronic submission of UDI data must send a letter containing all of the information required by § 830.310, as well as any ancillary information permitted to be submitted under § 830.340 that the labeler wishes to submit, within the time permitted by § 830.330, addressed to: UDI Regulatory Policy Support, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3293, Silver Spring, MD 20993-0002.
[78 FR 58826, Sept. 24, 2013, as amended at 85 FR 18443, Apr. 2, 2020]
# C_2014421EN.01006504.xml

| 24.11.2014 | EN | Official Journal of the European Union | C 421/65 |
| --- | --- | --- | --- |

24.11.2014

EN

Official Journal of the European Union

C 421/65

---

Order of the Civil Service Tribunal of 30 April 2014 — Lecolier v Commission

(Case F-18/14)

2014/C 421/100

Language of the case: French

The President of the First Chamber has ordered that the case be removed from the register.

---
**Exhibit 31.2****Certifications**I, Thomas J. Koenig, certify that:1. I have reviewed this annual report on Form 10-K of Day International Group, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report; 3. Based on my knowledge, the financial statements, and other financial information included inthis report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in thisreport; 4. The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and have:a) Designed such disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that material information relatingto the registrant, including its consolidated subsidiaries, is made known to us by otherswithin those entities, particularly during the period in which this report is being prepared;b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on such evaluation; andc) Disclosed in this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (the registrant’sfourth fiscal quarter in the case of an annual report) that has materially affected, or isreasonably likely to materially affect, the registrant’s internal control over financialreporting; and5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and theaudit committee of the registrant’s board of directors (or persons performing the equivalentfunctions):a) All significant deficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize and report financial information; andb) Any fraud, whether or not material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting.      Date: March 27, 2006 By:      /s/ Thomas J. Koenig       Thomas J. Koenig  Vice President and Chief Financial  Officer (Principal Financial Officer and  Principal Accounting Officer)
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1380 Catheter stylet. ( a ) *Identification.* A catheter stylet is a wire that is run through a catheter or cannula to render it stiff.
( b ) *Classification.* Class II (performance standards).
Exhibit 99.1


     CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


     In connection with the filing of the Quarterly Report on Form 10-QSB for
the Quarter Ended March 31, 2003 (the "Report"), by GVC Venture Corp. (the
"Registrant"), the undersigned hereby certifies that, to the best of his
knowledge:

1.   The Report fully  complies with the  requirements  of Section 13(a) or
     15(d)  of  the  Securities  Exchange  Act  of  1934,  as  amended,  as
     applicable; and
2.   The  information  contained  in the  Report  fairly  presents,  in all
     material respects,  the financial  condition and results of operations
     of the Registrant.




                                      /s/  Russell Banks
                                      ------------------------------------------
                                      Russell Banks
                                      Chairman of the Board of Directors
                                      (Principal Executive Officer) and Director

                                      May 15, 2003


A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 HAS BEEN
PROVIDED TO GVC VENTURE CORP. AND WILL BE RETAINED BY GVC VENTURE CORP., AND
FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.